About
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Key Points
Biologics (31% of sales)
Has one of the largest biosimilar pipelines comprising 28 molecules to be launched over the next decade. #
Only Indian company to get FDA approval for 3 biosimilar molecules (Trastuzumab, Pegfilgrastim and Insulin Glargine)
Aspires to reach $1bn revenues by FY22. #
Biologics division has been valued at $4.17bn as per the last fund raising round. # Biocon plans to list this division separately. #
Research services (32% of sales)
Syngene, the research services arm of biocon, was listed as an independent company in 2015.
Syngene is an integrated CDMO offering research, development and manufacturing services for small and large molecules, antibody-drug conjugates and oligonucleotides #
Small molecule generic segment (33% of sales)
Biocon has launched 4 generic products in the US market, 3 of them are statin products with market shares ranging from 15-20% and the last one is Tacrolimus. #
Novel biologics
Biocon's psoriasis drug Itolizumab received emergency use authorization from CDSCO for treating moderate-to-severe COVID-19 patients who develop the ‘cytokine storm'. Their US partner Equillium got a positive remark from FDA for Itolizumab and will initiate a global phase III trial. #
Biocon's US subsidiary Bicara therapeutics is developing novel immune-oncology asset (BCA101), fusion monoclonal antibody and is currently undergoing Phase 1/1b trial. #
Biocon is developing novel insulin drugs focusing on oncology, diabetes, auto-immune and immunology.